'European donor deferral' presentation slideshows

Consideration of Labeling Claims for TSE Agent Clearance in Plasma Derivatives

Consideration of Labeling Claims for TSE Agent Clearance in Plasma Derivatives . TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA. Reduction of possible risk of CJD and vCJD in Plasma Derivatives: FDA Recommendations. Donor deferrals: vCJD, vCJD risk

297 views • 10 slides